Advanced search
Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 38, 2019 - Issue 3
Submit an article Journal homepage
401
Views
14
CrossRef citations to date
0
Altmetric
Case Report

Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia

Justin B. HellmanDepartment of Ophthalmology and Vision Science, University of California Davis Health Eye Center, Sacramento, CA, USA
,
Ilana TraynisDepartment of Ophthalmology and Vision Science, University of California Davis Health Eye Center, Sacramento, CA, USA
&
Lily Koo LinDepartment of Ophthalmology and Vision Science, University of California Davis Health Eye Center, Sacramento, CA, USACorrespondence[email protected]
Pages 244-247 | Received 13 Feb 2018, Accepted 13 Jun 2018, Published online: 09 Jul 2018

References

  • Search of: pembrolizumab [Internet]. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/results?term=pembrolizumab. Accessed July 8, 2017.
  • Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–1117. doi:10.1016/S0140-6736(14)60958-2.
  • Beatty GL, O’Dwyer PJ, Clark J, et al. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 EPACADOSTAT (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res. 2017;23:3269–3276. doi:10.1158/1078-0432.CCR-16-2272.
  • Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–2391. doi:10.1093/annonc/mdv383.
  • Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 2017;19:21. doi:10.1007/s11886-017-0835-0.
  • Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532. doi:10.1056/NEJMoa1503093.
  • Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–225. doi:10.1016/j.ejca.2016.02.024.
  • Gonzalez NL, Puwanant A, Lu A, Marks SM, Zivkovic SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. Mar 2017;27:266–268. doi:10.1016/j.nmd.2017.01.002.
  • Vallet H, Gaillet A, Weiss N, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol. 2016;27:1352–1353. doi:10.1093/annonc/mdw126.
  • Berfelo F, Wilgenhof S, Brandsma D, Aronica E, Van Der Kooi A. Necrotizing myopathy, an ocular myasthenic syndrome and subclinical myocarditis associated with pembrolizumab treatment for metastatic melanoma. Neuromuscul Disord. 2016;26:214. doi:10.1016/j.nmd.2016.06.234.
  • A Phase 1/2 study exploring the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with Epacadostat (INCB024360) in subjects with selected cancers (INCB 24360-202/MK-3475-037/KEYNOTE-037/ECHO-202) - Clinicaltrials.gov. 2017. https://clinicaltrials.gov/ct2/show/NCT02178722. Accessed July 9, 2017.
  • Larkin J, Chiarion-Sileni V, Gonzalex R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. doi:10.1056/NEJMoa1504030.
  • Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845–1855. doi:10.1056/NEJMoa1611299.
  • Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50. doi:10.1186/s40425-016-0152-y.
  • Laubli H, Balmelli C, Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11. doi:10.1186/s40425-015-0057-1.
  • Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465. doi:10.1056/NEJMoa1200694.
  • Johnson DB, Blako JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755. doi:10.1056/NEJMoa1609214.
  • Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–136. doi:10.1016/j.ejca.2017.05.041.
  • Varricchi G, Marone G, Mercurio V, Galdiero MR, Bonaduce D, Tocchetti CG. Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem. 2018;25(11):1327–1339.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.